Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration

[1]  C. Stief,et al.  Prognostic value of pretreatment inflammatory markers in variant histologies of the bladder: is inflammation linked to survival after radical cystectomy? , 2020, World Journal of Urology.

[2]  M. Roscigno,et al.  The impact of histological variants on outcomes after open radical cystectomy for muscle-invasive urothelial bladder cancer: results from a single tertiary referral centre , 2020, World Journal of Urology.

[3]  M. Babjuk,et al.  Stratification of Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies. , 2020, European urology focus.

[4]  F. Saad,et al.  Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study , 2020, World Journal of Urology.

[5]  F. Saad,et al.  Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder. , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  J. Witjes,et al.  European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. , 2020, European urology.

[7]  M. Galsky,et al.  What Is the Significance of Variant Histology in Urothelial Carcinoma? , 2020, European urology focus.

[8]  M. Babjuk,et al.  EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. , 2019, European urology.

[9]  U. Capitanio,et al.  Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. , 2019, European urology.

[10]  W. Oyen,et al.  EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Shahrokh F. Shariat,et al.  European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. , 2019, European urology.

[12]  Junghoon Lee,et al.  BCG instillation versus radical cystectomy for high-risk NMIBC with squamous/glandular histologic variants , 2019, Scientific Reports.

[13]  M. Meng,et al.  Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer. , 2018, Clinical genitourinary cancer.

[14]  Tetsuya Shindo,et al.  Bacillus Calmette-Guérin may have clinical benefit for glandular or squamous differentiation in non-muscle invasive bladder cancer patients: retrospective multicenter study , 2018, Japanese journal of clinical oncology.

[15]  M. Amin,et al.  Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. , 2018, European Urology.

[16]  L. Kiemeney,et al.  Smoking intensity and bladder cancer aggressiveness at diagnosis , 2018, PloS one.

[17]  P. Capogrosso,et al.  Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer. , 2016, European urology focus.

[18]  A. Briganti,et al.  The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder , 2016, Nature Reviews Urology.

[19]  P. Humphrey,et al.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2016, European urology.

[20]  G. Hidas,et al.  The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer , 2016, Front. Oncol..

[21]  M. Colecchia,et al.  Usefulness of pT1 substaging in papillary urothelial bladder carcinoma , 2016, Diagnostic Pathology.

[22]  S. Porten,et al.  Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer , 2014, Current opinion in urology.

[23]  W. Lowrance,et al.  Comparative outcomes of pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation in patients treated with radical cystectomy. , 2011, The Journal of urology.

[24]  M. Duvdevani,et al.  Is radical cystectomy mandatory in every patient with variant histology of bladder cancer , 2011, Rare tumors.

[25]  U. Capitanio,et al.  Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. , 2009, The Journal of urology.

[26]  E. Messing,et al.  Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? , 2009, Urology.

[27]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[28]  E. Spitznagel,et al.  ASA Physical Status Classifications: A Study of Consistency of Ratings , 1978, Anesthesiology.